Matches in SemOpenAlex for { <https://semopenalex.org/work/W2178540982> ?p ?o ?g. }
- W2178540982 endingPage "273.e8" @default.
- W2178540982 startingPage "273.e1" @default.
- W2178540982 abstract "Antiphospholipid syndrome is defined by the combination of thrombotic events and/or obstetric morbidity in patients who have tested positive persistently for antiphospholipid antibodies. With good treatment, approximately 70% of pregnant women with antiphospholipid syndrome will deliver a viable live infant. However, current management does not prevent all maternal, fetal, and neonatal complications of antiphospholipid syndrome.This observational, retrospective, single-center cohort study aimed to assess pregnancy outcome in women with antiphospholipid antibodies who were treated with hydroxychloroquine in addition to conventional treatment during pregnancy.One-hundred seventy pregnancies in 96 women with persistent antiphospholipid antibodies were analyzed: (1) 51 pregnancies that occurred in 31 women were treated with hydroxychloroquine for at least 6 months before pregnancy, and the therapy continued throughout gestation (group A); (2) 119 pregnancies that occurred in 65 women with antiphospholipid antibodies that were not treated with hydroxychloroquine were included as controls (group B).Hydroxychloroquine-treatment was associated with a higher rate of live births (67% group A vs 57% group B; P = .05) and a lower prevalence of antiphospholipid antibodies-related pregnancy morbidity (47% group A vs 63% B; P = .004). The association of hydroxychloroquine with a lower rate of any complication in pregnancy was confirmed after multivariate analysis (odds ratio, 2.2; 95% confidence interval, 1.2-136; P = .04). Fetal losses at >10 weeks of gestation (2% vs 11%; P = .05) and placenta-mediated complications (2% vs 11%; P = .05) were less frequent in group A than group B. Pregnancy duration was longer in group A than group B (27.6 [6-40] vs 21.5 [6-40] weeks; P = .03). There was a higher rate of spontaneous vaginal labor in hydroxychloroquine-treated women compared with group B (37.3% vs 14.3%; P = .01).Despite the heterogeneity in the 2 groups in terms of systemic lupus erythematosus prevalence and previous pregnancy history, our results support the concept that women with antiphospholipid antibodies may benefit from treatment with hydroxychloroquine during pregnancy to improve pregnancy outcome. The addition of hydroxychloroquine to conventional treatment is worthy of further assessment in a proper designed randomized controlled trial." @default.
- W2178540982 created "2016-06-24" @default.
- W2178540982 creator A5015749384 @default.
- W2178540982 creator A5017039749 @default.
- W2178540982 creator A5041411751 @default.
- W2178540982 creator A5043181396 @default.
- W2178540982 creator A5067306587 @default.
- W2178540982 creator A5076862699 @default.
- W2178540982 date "2016-02-01" @default.
- W2178540982 modified "2023-10-18" @default.
- W2178540982 title "The impact of hydroxychloroquine treatment on pregnancy outcome in women with antiphospholipid antibodies" @default.
- W2178540982 cites W1521045812 @default.
- W2178540982 cites W1963494811 @default.
- W2178540982 cites W1966792319 @default.
- W2178540982 cites W1981463160 @default.
- W2178540982 cites W1982511037 @default.
- W2178540982 cites W2004135257 @default.
- W2178540982 cites W2014873778 @default.
- W2178540982 cites W2017275815 @default.
- W2178540982 cites W2019151860 @default.
- W2178540982 cites W2034890148 @default.
- W2178540982 cites W2043383287 @default.
- W2178540982 cites W2049326681 @default.
- W2178540982 cites W2054330426 @default.
- W2178540982 cites W2054542615 @default.
- W2178540982 cites W2056493149 @default.
- W2178540982 cites W2056692578 @default.
- W2178540982 cites W2064513816 @default.
- W2178540982 cites W2064568183 @default.
- W2178540982 cites W2066451005 @default.
- W2178540982 cites W2066719903 @default.
- W2178540982 cites W2068106248 @default.
- W2178540982 cites W2069797332 @default.
- W2178540982 cites W2070527591 @default.
- W2178540982 cites W2077806147 @default.
- W2178540982 cites W2088887888 @default.
- W2178540982 cites W2093796906 @default.
- W2178540982 cites W2133473874 @default.
- W2178540982 cites W2157038471 @default.
- W2178540982 cites W4211023937 @default.
- W2178540982 cites W4230134211 @default.
- W2178540982 cites W4254977219 @default.
- W2178540982 doi "https://doi.org/10.1016/j.ajog.2015.09.078" @default.
- W2178540982 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26429521" @default.
- W2178540982 hasPublicationYear "2016" @default.
- W2178540982 type Work @default.
- W2178540982 sameAs 2178540982 @default.
- W2178540982 citedByCount "127" @default.
- W2178540982 countsByYear W21785409822015 @default.
- W2178540982 countsByYear W21785409822016 @default.
- W2178540982 countsByYear W21785409822017 @default.
- W2178540982 countsByYear W21785409822018 @default.
- W2178540982 countsByYear W21785409822019 @default.
- W2178540982 countsByYear W21785409822020 @default.
- W2178540982 countsByYear W21785409822021 @default.
- W2178540982 countsByYear W21785409822022 @default.
- W2178540982 countsByYear W21785409822023 @default.
- W2178540982 crossrefType "journal-article" @default.
- W2178540982 hasAuthorship W2178540982A5015749384 @default.
- W2178540982 hasAuthorship W2178540982A5017039749 @default.
- W2178540982 hasAuthorship W2178540982A5041411751 @default.
- W2178540982 hasAuthorship W2178540982A5043181396 @default.
- W2178540982 hasAuthorship W2178540982A5067306587 @default.
- W2178540982 hasAuthorship W2178540982A5076862699 @default.
- W2178540982 hasBestOaLocation W21785409822 @default.
- W2178540982 hasConcept C126322002 @default.
- W2178540982 hasConcept C131872663 @default.
- W2178540982 hasConcept C156957248 @default.
- W2178540982 hasConcept C2776874634 @default.
- W2178540982 hasConcept C2778279030 @default.
- W2178540982 hasConcept C2779123688 @default.
- W2178540982 hasConcept C2779134260 @default.
- W2178540982 hasConcept C2779234561 @default.
- W2178540982 hasConcept C2780868729 @default.
- W2178540982 hasConcept C3008058167 @default.
- W2178540982 hasConcept C46973012 @default.
- W2178540982 hasConcept C524204448 @default.
- W2178540982 hasConcept C54355233 @default.
- W2178540982 hasConcept C71924100 @default.
- W2178540982 hasConcept C86803240 @default.
- W2178540982 hasConceptScore W2178540982C126322002 @default.
- W2178540982 hasConceptScore W2178540982C131872663 @default.
- W2178540982 hasConceptScore W2178540982C156957248 @default.
- W2178540982 hasConceptScore W2178540982C2776874634 @default.
- W2178540982 hasConceptScore W2178540982C2778279030 @default.
- W2178540982 hasConceptScore W2178540982C2779123688 @default.
- W2178540982 hasConceptScore W2178540982C2779134260 @default.
- W2178540982 hasConceptScore W2178540982C2779234561 @default.
- W2178540982 hasConceptScore W2178540982C2780868729 @default.
- W2178540982 hasConceptScore W2178540982C3008058167 @default.
- W2178540982 hasConceptScore W2178540982C46973012 @default.
- W2178540982 hasConceptScore W2178540982C524204448 @default.
- W2178540982 hasConceptScore W2178540982C54355233 @default.
- W2178540982 hasConceptScore W2178540982C71924100 @default.
- W2178540982 hasConceptScore W2178540982C86803240 @default.
- W2178540982 hasIssue "2" @default.
- W2178540982 hasLocation W21785409821 @default.
- W2178540982 hasLocation W21785409822 @default.